Cyramza First-Line Lung Cancer Bid Raises Clinical Practice Questions

Lilly Drug Wins Narrow FDA Advisory Committee Backing

 
• By Sue Sutter
  
Runner jumping over running hurdle, low angle view
Lilly surmounted the ODAC hurdle, but more obstacles may lay ahead for Cyramza in first-line lung cancer • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip